Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Anna WeissOlga Martínez-SáezAdrienne G WaksAlison LawsMonica McGrathPaolo TarantinoLeah H PortnowEric WinerMaría ReyMarta TapiaAleix PratAnn H PartridgeSara M TolaneyJuan M CejalvoElizabeth A MittendorfTari A KingPublished in: Cancer (2023)
Among patients who had cT1-cT2N0M0, HER2-positive breast cancer, approximately 20% who underwent upfront surgery were pN-positive, and the rate reached 25% for those with cT1c tumors. Given the opportunity for tailored therapy among lymph node-positive, HER2-positive patients, these data provide rationale for future analyses investigating the utility of routine axillary imaging in patients with HER2-positive breast cancer.
Keyphrases
- positive breast cancer
- lymph node
- epidermal growth factor receptor
- image quality
- dual energy
- computed tomography
- contrast enhanced
- neoadjuvant chemotherapy
- tyrosine kinase
- end stage renal disease
- ejection fraction
- newly diagnosed
- positron emission tomography
- endothelial cells
- minimally invasive
- advanced non small cell lung cancer
- high resolution
- sentinel lymph node
- prognostic factors
- magnetic resonance imaging
- coronary artery bypass
- clinical trial
- squamous cell carcinoma
- patient reported outcomes
- electronic health record
- ultrasound guided
- current status
- early stage
- big data
- induced pluripotent stem cells
- data analysis
- mass spectrometry
- locally advanced
- rectal cancer